Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both

James, Nicholas D.; Pirrie, Sarah; Pope, Ann; Barton, Darren; Andronis, Lazaros; Goranitis, Ilias; Collins, Stuart; Daunton, Adam; McLaren, Duncan B.; O’Sullivan, Joe M.; Parker, Christopher; Porfiri, Emilio; Staffurth, John; Stanley, Andrew; Wylie, James; Beesley, S.; Birtle, Alison; Brown, Janet; Chakraborti, Prabir; Hussain, Syed A.; Russell, Martin; Billingham, Lucinda

doi:10.1001/jamaoncol.2015.5570

Cited by 80 publications

(66 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…230 The randomized TRAPEZE trial used a 232 factorial design to compare clinical PFS (pain progression, SREs, or death) as the primary outcome in 757 men with bone metastatic CRPC treated with docetaxel alone or with zoledronic acid, 89Sr, or both. 231 The bone-directed therapies had no statistically significant effect on the primary outcome or on OS in unadjusted analysis. However, adjusted analysis revealed a small effect for 89Sr on clinical PFS (HR, 0.85; 95% CI, 0.73-0.99; P5.03).…”

Section: Agents Related To Bone Health In Crpcmentioning

confidence: 89%

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Mohler

Antonarakis

Armstrong

et al. 2019

Journal of the National Comprehensive Cancer Network

1,088

841

View full text Add to dashboard Cite

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.

show abstract

Section: Agents Related To Bone Health In Crpcmentioning

confidence: 89%

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Mohler

Antonarakis

Armstrong

et al. 2019

Journal of the National Comprehensive Cancer Network

1,088

841

View full text Add to dashboard Cite

show abstract

“…When looking at SSE, two prospective randomised studies in men with mCRPC demonstrated an advantage. The TRAPEZE study showed a significant delay in SSEs when docetaxel was combined with zoledronic acid as compared with docetaxel alone and that the combination was safe, but there was no improvement in OS [128]. Interestingly, the benefit in delaying SSEs was in the same range as what was seen in the pivotal zoledronic acid study when chemotherapy was not in use.…”

mentioning

confidence: 95%

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

et al. 2018

View full text Add to dashboard Cite

The second Advanced Prostate Cancer Consensus Conference APCCC 2017 did provide a forum for discussion and debates on current treatment options for men with advanced prostate cancer. The aim of the conference is to bring the expertise of world experts to care givers around the world who see less patients with prostate cancer. The conference concluded with a discussion and voting of the expert panel on predefined consensus questions, targeting areas of primary clinical relevance. The results of these expert opinion votes are embedded in the clinical context of current treatment of men with advanced prostate cancer and provide a practical guide to clinicians to assist in the discussions with men with prostate cancer as part of a shared and multidisciplinary decision-making process.

show abstract

“…The concept of targeting bone and tumour is not novel. Prior studies have examined docetaxel in combination with bone-targeting agents that are not known to prolong survival, namely, strontium-89 and rhenium-188-hydroxyethylidine diphosphonate [14,15]. These studies only used one or two doses of the bone-seeking radiopharmaceutical, rather than as a repetitively dosed regimen integrated with chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial

Morris

Loriot

Sweeney

et al. 2019

European Journal of Cancer

View full text Add to dashboard Cite

Radium 223 dichloride (radium-223) is an alpha particleeemitting bonedirected therapy that prolongs overall survival in men with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). Docetaxel is an antimicrotubule cytotoxic agent that improves survival in mCRPC. We investigated whether combining these potentially cross-sensitising agents to dually target tumour and bone would be safe and effective. Patients and methods: Phase 1 was a dose escalation study to define a recommended phase 2 dose (RP2D) of docetaxel and radium-223. In phase 2a, patients were randomised 2:1 to the recommended combination regimen or docetaxel at a dose of 75 mg/m 2 every 3 weeks (q3w). Patients with bone-predominant mCRPC were eligible. End-points were safety, efficacy and treatment-related changes in serum and imaging biomarkers. Results: Twenty patients were enrolled in phase 1; 53 patients were randomised in phase 2a: 36 to combination treatment and 17 to docetaxel alone. The RP2D for the combination was radium-223 55 kBq/kg every six weeks Â 5 doses, plus docetaxel 60 mg/m 2 q3w Â 10 doses. Febrile neutropenia was dose limiting. A higher rate of febrile neutropenia was seen in the docetaxel monotherapy arm (15% vs 0%); the safety profile of the treatment groups was otherwise similar. The combination arm had more durable suppression of prostate-specific antigen (median time to progression, 6.6 vs 4.8 months, respectively), alkaline phosphatase (9 vs 7 months) and osteoblastic bone deposition markers. Conclusions: Radium-223 in combination with docetaxel at the RP2D was well tolerated. Exploratory efficacy data suggested enhanced antitumour activity for the combination relative to docetaxel alone. Comparative studies with end-points of clinical benefit are warranted. ClinicalTrials.gov number: NCT01106352.

show abstract

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both

Abstract: isrctn.com Identifier: ISRCTN12808747.

Cited by 80 publications

References 15 publications

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial

Contact Info

Product

Resources

About